Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy

Avcıbaşı, Uğur; Avcıbaşı, Nesibe; Akalın, Hilmi Arkut; Ediz, Melis; Demiroğlu, Hasan; Gümüşer, Fikriye Gül; Özçalışkan, Emir; Türkcan, Ceren; Uygun, Deniz Aktaş; Akgöl, Sinan

doi:10.1007/s11051-013-2021-7

Cited by 11 publications

(5 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthesis of functional monomer APH was carried out by the procedure of condensation reaction by Hubacher [35] with minor modifications [36]. Briefly, 10 g of AlCl 3 was mixed with 50 ml of nitrobenzene.…”

Section: 2a Preparation Of Aph Monomermentioning

confidence: 99%

“…Then this product was refluxed with acetic acid, water and H 2 SO 4 for 4 h. Residual product was then dissolved in boiling HCl (1.0 N) and mixed with water and cooled down to 5 • C. Filtrated material was washed with NH 4 OH and crystallized by methanol. Further characterization of the APH monomer can be found in the literature of our research group [36].…”

Section: 2a Preparation Of Aph Monomermentioning

confidence: 99%

“…Magnetic poly(HEMA-APH) nanoparticles were synthesized by surfactant-free polymerization method [36,37]. Briefly, 0.5 g of PVA dissolved in 45 ml of water and transferred to a polymerization reactor.…”

Section: 2b Preparation Of Magnetic Poly(hema-aph) Nanoparticlesmentioning

confidence: 99%

See 2 more Smart Citations

Hydrophobic nano-carrier for lysozyme adsorption

et al. 2016

View full text Add to dashboard Cite

In this work, poly(HEMA-APH) nanoparticles were synthesized by surfactant-free emulsion polymerization technique. Magnetic behaviour was introduced by simple addition of Fe 3 O 4 into the polymerization medium. Characterization of the nanoparticle was carried out by FTIR, ESR, SEM, AFM and EDX analyses. These synthesized magnetic nanoparticles were used for adsorption of lysozyme. For this purpose, adsorption conditions were optimized and maximum lysozyme binding capacity was found to be 278.8 mg g −1 polymer in pH 7.0 phosphate buffer at 25 • C. Desorption and reusability properties of the nanoparticles were investigated and lysozyme adsorption efficiency did not change significantly at the end of the 10 successive reuses.

show abstract

Section: 2a Preparation Of Aph Monomermentioning

confidence: 99%

Section: 2a Preparation Of Aph Monomermentioning

confidence: 99%

See 1 more Smart Citation

Hydrophobic nano-carrier for lysozyme adsorption

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Iodine-131 is a radioisotope with a half-life of nearly 8 days and an energy of 364 keV of gamma radiation (Jimenez et al 2019 ; Saha and Saha 2004 ). Such properties of 131 I made it a suitable radionuclide to be applied in radiokinetic studies (Rashed et al 2017b ; Avcıbaşı et al 2013 ; Bayrak et al 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique

Shewaiter,

Selim,

Rashed

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background This work aimed to prepare niosomal formulations of an anticancer agent [mefenamic acid (MEF)] to enhance its cancer targeting. 131I was utilized as a radiolabeling isotope to study the radio-kinetics of MEF niosomes. Methods niosomal formulations were prepared by the ether injection method and assessed for entrapment efficiency (EE%), zeta potential (ZP), polydispersity index (PDI) and particle size (PS). MEF was labeled with 131I by direct electrophilic substitution reaction through optimization of radiolabeling-related parameters. In the radio-kinetic study, the optimal 131I-MEF niosomal formula was administered intravenously (I.V.) to solid tumor-bearing mice and compared to I.V. 131I-MEF solution as a control. Results the average PS and ZP values of the optimal formulation were 247.23 ± 2.32 nm and − 28.3 ± 1.21, respectively. The highest 131I-MEF labeling yield was 98.7 ± 0.8%. The biodistribution study revealed that the highest tumor uptake of 131I-MEF niosomal formula and 131I-MEF solution at 60 min post-injection were 2.73 and 1.94% ID/g, respectively. Conclusion MEF-loaded niosomes could be a hopeful candidate in cancer treatment due to their potent tumor uptake. Such high targeting was attributed to passive targeting of the nanosized niosomes and confirmed by radiokinetic evaluation.

show abstract

“…Nanotechnology holds great promise to revolutionize the field of medicine and has brought challenging innovations in diagnosis and treatment of diseases, in particular building contrast agents for various imaging modalities and delivering biologically active substances to specific tissues or organs [ 24 , 25 , 26 ]. Recent advances in nanomedicine have shown that multiple types of nanoparticles (NPs) can be labeled with radionuclides for nuclear medicine imaging and therapy, such as liposomes, micelles, polymers, metal oxide NPs and dendrimers [ 27 , 28 , 29 , 30 , 31 ]. These NPs display improved diagnostic and therapeutic effects, lower toxicity and controllable biodistribution, compared with conventional small molecule radiopharmaceuticals.…”

Section: Introductionmentioning

confidence: 99%

Radiolabeled Dendrimers for Nuclear Medicine Applications

Zhao

Zhu

et al. 2017

Molecules

View full text Add to dashboard Cite

Recent advances in nuclear medicine have explored nanoscale carriers for targeted delivery of various radionuclides in specific manners to improve the effect of diagnosis and therapy of diseases. Due to the unique molecular architecture allowing facile attachment of targeting ligands and radionuclides, dendrimers provide versatile platforms in this filed to build abundant multifunctional radiolabeled nanoparticles for nuclear medicine applications. This review gives special focus to recent advances in dendrimer-based nuclear medicine agents for the imaging and treatment of cancer, cardiovascular and other diseases. Radiolabeling strategies for different radionuclides and several challenges involved in clinical translation of radiolabeled dendrimers are extensively discussed.

show abstract

Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy

Cited by 11 publications

References 110 publications

Hydrophobic nano-carrier for lysozyme adsorption

Hydrophobic nano-carrier for lysozyme adsorption

Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique

Radiolabeled Dendrimers for Nuclear Medicine Applications

Contact Info

Product

Resources

About